Skip to content
Study details
Enrolling now

tVNS in Long COVID-19

Icahn School of Medicine at Mount Sinai
NCT IDNCT06585254ClinicalTrials.gov data as of Apr 2026
Target enrollment

50

Study length

about 2.2 years

Ages

21–70

Locations

1 site in NY

About this study

Researchers are testing a treatment called transcutaneous vagus nerve stimulation (tVNS) to see if it improves the health of people with long COVID. The trial will compare two different settings for the tVNS device and see which one works best over 6 weeks, with those who use their assigned device for at least 30 out of 42 opportunities receiving the best setting for another 6 weeks.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Use Transcutaneous vagus nerve stimulator
Primary goalChange in Short Form Health Survey (SF-36)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Change in Short Form Health Survey (SF-36), The Chalder Fatigue Questionnaire (CFQ), VAS measuring Postexertional malaise (PEM), VAS measuring brain fog, VAS to measure Widespread Pain, Visual Analog Scale (VAS) measuring Fatigue

Secondary: Heart Rate Variability (HRV)

Devices

therapeutic